CVE:TLT Theralase Technologies (TLT) Stock Price, News & Analysis → Write this ticker symbol down… (From StocksToTrade) (Ad) Free TLT Stock Alerts C$0.20 +0.01 (+2.63%) (As of 06/7/2024 08:54 PM ET) Add Compare Share Share Today's RangeC$0.19▼C$0.2050-Day RangeC$0.14▼C$0.2052-Week RangeC$0.14▼C$0.31Volume90,009 shsAverage Volume136,739 shsMarket CapitalizationC$46.66 millionP/E RatioN/ADividend Yield1,487.18%Price TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesInsider TradesStock AnalysisChartEarningsHeadlinesInsider Trades Get Theralase Technologies alerts: Email Address Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Theralase Technologies Stock (CVE:TLT)Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin - Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology that accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. The company is based in Toronto, Canada.Read More TLT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TLT Stock News HeadlinesMay 2, 2024 | finance.yahoo.comTheralase(R) Expands Clinical TeamApril 24, 2024 | finanznachrichten.deTheralase Technologies Inc.: Theralase Closes $CAN 750,000 Non-Brokered Private PlacementApril 5, 2024 | finanznachrichten.deTheralase Technologies Inc.: Theralase Granted Canadian Cancer Vaccine PatentApril 5, 2024 | finance.yahoo.comTheralase(R) Granted Canadian Cancer Vaccine PatentMarch 26, 2024 | finance.yahoo.comTheralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological AssociationMarch 16, 2024 | theglobeandmail.comClosing Bell: Theralase Technologies Inc flat on Friday (TLT)March 1, 2024 | morningstar.comTheralase Technologies Inc TLTFebruary 12, 2024 | finanznachrichten.deTheralase Technologies Inc.: Theralase Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's DiseaseFebruary 12, 2024 | finance.yahoo.comTheralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's DiseaseFebruary 8, 2024 | finance.yahoo.comDr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical StudyFebruary 5, 2024 | finanznachrichten.deTheralase Technologies Inc.: Theralase Closes $CAN 1.2 Million Non-Brokered Private PlacementFebruary 5, 2024 | finance.yahoo.comTheralase(R) Closes $CAN 1.2 Million Non-Brokered Private PlacementJanuary 15, 2024 | finanznachrichten.deTheralase Technologies Inc.: Theralase Provides Update on Phase II Bladder Cancer Clinical StudyDecember 1, 2023 | proactiveinvestors.comTheralase makes positive progress on Phase II study on...Theralase makes positive progress on Phase II study on bladder...November 30, 2023 | proactiveinvestors.comTheralase concludes $1.17M private placement for cancer treatment advancementsNovember 30, 2023 | proactiveinvestors.comTheralase focused on breakthrough designation after positive preliminary study dataNovember 29, 2023 | finanznachrichten.deTheralase Technologies Inc.: Theralase Release's 3Q2023 Interim Financial StatementsNovember 29, 2023 | finance.yahoo.comTheralase Release's 3Q2023 Interim Financial StatementsNovember 29, 2023 | finanznachrichten.deTheralase Technologies Inc.: Theralase Closes $CAN 1.17 Million Non-Brokered Private PlacementNovember 17, 2023 | finanznachrichten.deTheralase Technologies Inc.: Theralase Commences Non-Brokered Private Placement and Termination of Previously Announced FinancingNovember 17, 2023 | finance.yahoo.comTheralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced FinancingOctober 23, 2023 | benzinga.comTheralase(R) Announces Brokered LIFE FinancingOctober 23, 2023 | finance.yahoo.comTheralase(R) Optimizes Phase II Bladder Cancer Clinical StudyOctober 16, 2023 | finance.yahoo.comTheralase(R) Provides Update on Bladder Cancer Clinical StudyOctober 10, 2023 | theglobeandmail.comClosing Bell: Theralase Technologies Inc WT up on Friday (TLT-WT)See More Headlines Receive TLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theralase Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today6/10/2024Next Earnings (Estimated)9/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolCVE:TLT CUSIPN/A CIKN/A Webtheralase.com Phone+1-416-6995273FaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-4,570,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-182.91% Return on Assets-77.21% Debt Debt-to-Equity Ratio20.30 Current Ratio1.39 Quick Ratio3.40 Sales & Book Value Annual SalesC$1.07 million Price / Sales43.61 Cash FlowC$0.01 per share Price / Cash Flow30.45 Book ValueC$0.01 per share Price / Book19.50Miscellaneous Outstanding Shares239,300,000Free FloatN/AMarket CapC$46.66 million OptionableNot Optionable Beta1.59 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMs. Kristina Hachey CPACFO & DirectorDr. Arkady Mandel DSc.M.D., Ph.D., Chief Scientific Officer & DirectorMr. Roger John Dumoulin-White B.Sc.P.Eng., President, CEO & DirectorMr. David M. Groves B.APresident of World Trade DivisionDr. Terry Ruch DVMEquine Medical ConsultantKey CompetitorsProtech Home MedicalCVE:PHMHelius Medical TechnologiesTSE:HSMVentriPoint DiagnosticsCVE:VPTMedX HealthCVE:MDXAurora SpineCVE:ASGView All CompetitorsInsidersMatthew Thomas PerratonBought 900 shares on 1/4/2024Total: C$176.49 ($0.20/share)View All Insider Transactions TLT Stock Analysis - Frequently Asked Questions How have TLT shares performed in 2024? Theralase Technologies' stock was trading at C$0.18 at the beginning of the year. Since then, TLT stock has increased by 11.4% and is now trading at C$0.20. View the best growth stocks for 2024 here. When is Theralase Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, September 3rd 2024. View our TLT earnings forecast. How were Theralase Technologies' earnings last quarter? Theralase Technologies Inc. (CVE:TLT) released its quarterly earnings results on Wednesday, March, 27th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $0.36 million for the quarter. Is Theralase Technologies a good dividend stock? Theralase Technologies (CVE:TLT) pays an annual dividend of C$2.90 per share and currently has a dividend yield of 2.03%. What other stocks do shareholders of Theralase Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Theralase Technologies investors own include IMRIS (IMRSQ), Cross Timbers Royalty Trust (CRT), Aurora Cannabis (ACB), AGNC Investment (AGNC), InfraCap MLP ETF (AMZA), Alliance Resource Partners (ARLP), Ford Motor (F), Gladstone Investment (GAIN) and Heat Biologics (HTBX). How do I buy shares of Theralase Technologies? Shares of TLT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:TLT) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theralase Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theralase Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.